NCT04504331 2026-02-12
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Phase 1 Terminated
Clinical Trials
23 trialsNCT04570956 2026-01-23
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
Mayo Clinic
Phase 2 Terminated
NCT05128773 2025-09-16
AMEERA-6
Sanofi
Phase 3 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT02936206 2021-05-19
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT02395627 2020-07-07
Reversing Therapy Resistance With Epigenetic-Immune Modification
University of California, San Francisco
Phase 2 Terminated
NCT00096369 2019-01-24
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00873366 2018-01-23
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
Mayo Clinic
Terminated
NCT00290654 2017-12-28
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT00206492 2017-08-01
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
Baylor Breast Care Center
Phase 2 Terminated
NCT00899197 2017-08-01
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Wake Forest University Health Sciences
Terminated
NCT02322853 2017-05-24
OLYMPE
Centre Francois Baclesse
Phase 2 Terminated
NCT00066807 2016-10-28
PERCHE
ETOP IBCSG Partners Foundation
Phase 3 Terminated
NCT01194908 2015-01-26
Re-expression of ER in Triple Negative Breast Cancers
Emory University
Phase 1/2 Terminated
NCT00053911 2014-12-16
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
UNICANCER
Phase 3 Terminated
NCT00183963 2014-05-22
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
University of Southern California
Phase 2 Terminated
NCT01194427 2013-05-17
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00002772 2013-01-24
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT00016276 2013-01-16
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00532454 2010-02-10
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
National Cancer Center, Korea
Phase 2 Terminated
NCT00210028 2006-11-14
Study Assessing Efficacy of ZARNESTRAâ„¢ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
Institut Claudius Regaud
Phase 2 Terminated